StockWatch
·

BIOGEN INC. Q2 FY26 Results

BIIBQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue2.7K10.4%3.4%
Total Income2.7K10.4%3.4%
Expenditure2.6K24.0%36.9%
PBT132.4065.0%82.2%
Net Profit97.5069.5%84.6%
OPM—
NPM3.56%9.33pp20.43pp
EPS0.6669.6%84.8%
View full financials

Biogen Inc. Provides Preliminary Financial Estimates for Q2 and Q3 2026

02 Jul 2026 · 2 Jul, 1:43 am

Summary

Biogen Inc. has provided preliminary financial estimates for the second and third quarters of 2026, focusing on anticipated acquired in-process research and development, upfront, and milestone expenses. For Q2 2026, the company expects these expenses to be approximately $164 million pre-tax, impacting diluted EPS by about $0.95. For Q3 2026, the anticipated expense range is $290 million to $320 million, with a projected EPS impact of $1.75 to $1.95 per share. These figures relate to potential milestones and transactions that have not yet closed, and the company notes that final results are subject to closing procedures and may differ from these preliminary estimates.

Key Highlights

  1. 1

    Biogen expects acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis for the second quarter of 2026.

  2. 2

    The estimated charge for Q2 2026 is expected to impact GAAP and non-GAAP net income per diluted share by approximately $0.95 per share.

  3. 3

    For the third quarter of 2026, Biogen anticipates acquired in-process research and development, upfront and milestone expense ranging from approximately $290 million to $320 million.

  4. 4

    The estimated charge for Q3 2026 is anticipated to impact GAAP and non-GAAP net income per diluted share ranging from approximately $1.75 to $1.95 per share.

Informational and educational content only. Not investment advice.